(This document is an English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.)

September 2, 2026

Company name:	Hodogaya Chemical Co., Ltd.
Name of representative:	Yuto Matsumoto, President and Representative Director (Securities code: 4112, Prime Market of Tokyo Stock Exchange)
Inquiries:	Hideaki Hashizume, Executive Officer & General Manager Corporate Planning Department (Telephone: +81-3-6852-0327)

Notice Regarding the Establishment of a Subsidiary

Hodogaya Chemical Co., Ltd. (the "Company") hereby announces that it has established a subsidiary to promote the nucleic acid therapeutics CDMO business as of September 1, 2026, as detailed below.

1. Purpose of Establishment

In its Mid-term Management Plan "CODE/CHORD 2030," announced on May 15, 2026, the Company identified its entry into the nucleic acid therapeutics CDMO business as a new growth driver following its OLED materials business. In the biomaterials field, the Hodogaya Chemical Group has leveraged its established manufacturing infrastructure and high agility in small-batch, high-variety production to develop proprietary raw materials and expand the contract synthesis of research-grade and non-GMP oligonucleotides through SFC CO., LTD. (South Korea) The new company has been established to leverage these technologies and expertise and to advance the commercialization of the CDMO business, with the aim of providing integrated services from raw materials to GMP manufacturing in the field of nucleic acid therapeutics. Going forward, the Company plans to construct a new building at its Koriyama Plant equipped with manufacturing facilities and cleanrooms for the production of drug substances for nucleic acid therapeutics, to provide one-stop services to customers in Japan and overseas, including academic institutions and pharmaceutical companies.

In addition, YUKI GOSEI KOGYO CO., LTD. ("YGK") possesses sophisticated manufacturing and quality control systems based on GMP standards cultivated through its long-standing small molecule pharmaceutical manufacturing business, as well as knowledge and expertise in the manufacturing of nucleic acid-related compounds. (For details, please refer to the announcement dated February 26, 2026, titled "Notice Concerning Collaboration with YUKI GOSEI KOGYO CO., LTD. (Securities Code: 4531) and Share Acquisition Corresponding to the Accumulation of Shares"). Furthermore, the Company will consider a potential transition to a joint venture structure between the Hodogaya Chemical Group and YGK in the future.

2. Overview of the Subsidiary

1) Name	NuChord
2) Location	1-9-2 Higashi-Shimbashi, Minato-ku, Tokyo
3) Representative	Hikaru Hoshikawa, President and Representative Director
4) Business activities	Research and development, manufacture, and sale of pharmaceuticals and biotechnology-related products, as well as contract research, development, and manufacturing services, primarily in the field of nucleic acid therapeutics
5) Capital	200 million yen
6) Date of establishment	September 1, 2026
7) Fiscal year-end	March
8) Ownership ratio	100% owned by the Company
9) Relationship with the Company	Capital relationship: The Company holds 100% of the issued shares. Personnel relationship: Directors and employees of the Company will serve as officers of, or be seconded to, the subsidiary. Business relationship: None, as the subsidiary is newly established.

3. Future Outlook

The impact of this matter on the Company's consolidated financial results for the fiscal year ending March 31, 2027 is immaterial. Going forward, if any event occurs that significantly impacts the Company's consolidated financial results, we will disclose it promptly.
Although this matter does not fall under the timely disclosure standards established by the Tokyo Stock Exchange, Inc., this announcement is disclosed voluntarily for the purpose of providing appropriate information to investors.